Dermatology Times, January 2021 (Vol. 42, No. 1)

Combination Rosacea Therapy Improves Outcome

January 29, 2021

Experts are recommending combination therapies as a way to treat rosacea, according to a presentation at ODAC Dermatology, Aesthetic and Surgical Conference 2021 Pre-Conference Sneak Peek Inflammatory Diseases Virtual Symposium.

Tips for Navigating Practice Challenges During COVID-19

January 21, 2021

George Martin, MD, program director of the 2021 Maui Derm Live and Maui Derm Connect annual conferences being held January 25-29 in Maui, Hawaii, shares his checklist of essential advice for optimizing practice management during the COVID-19 pandemic.

Pathogens, Microbiota May Impact Rosacea

January 20, 2021

One expert says the action of demodex folliculorum and the composition of the symbiotic microbiota in the skin of patients with rosacea may provide valuable insights into the pathogenesis and pathophysiology of this widespread skin disease.

Immunity Induction Therapy with Antibodies, Wound-Healing Therapies Show Potential

January 14, 2021

Acne research delineating molecular and cellular pathogenic pathways gives insight into new therapeutic targets. According to a recent review, biologics and other therapies that modulate scar formation and wound healing will have value for treating severe acne.

Study Examines Finasteride Risks for Younger Males

January 12, 2021

A recent study shows an association between finasteride use and psychological adverse events (AEs) including suicidality. Dermatologists should weigh benefits and risks carefully when considering finasteride for certain patients with hair loss, according to one expert.

Top 20 trending stories of 2020

December 11, 2020

For 2020, trending topics can be summed up in one word: COVID-19. But, even during a pandemic, dermatologists and the medical community at large continued to research novel therapies and seek new solutions for providing the best possible patient care. Here, Dermatology Times tracks the most compelling topics of an unprecedented year.

Utility of PRAME staining in identifying malignant transformation of melanocytic nevi

December 09, 2020

Recently, PRAME (preferentially expressed antigen in melanoma) immunohistochemical staining has shown its usefulness in distinguishing benign from malignant melanocytic cell populations, offering another color to the canvas in the quest for a more definitive diagnosis of melanoma.